Shuttle Pharmaceuticals is no longer a glioblastoma-drug story. Management shut the Phase 2 radiation-sensitizer program in November and spent the following months converting a Nasdaq listing into a Dogecoin mining vehicle. The early-May close of the United Dogecoin merger, paired with a nine-million-class private placement, is the event that rewrote the residual claim. Common holders now sit behind convertible preferred, milestone warrants, and a going-concern warning that the latest quarterly filing still carries.
Research spending collapsed after the trial wind-down. Cash at the March quarter-end sat just above $1 million against a working-capital hole of nearly $6 million. The March common sale added about $4 million of gross proceeds and still left management saying existing resources do not fund twelve months of operations. The Molecule.ai platform sits on the balance sheet as a large intangible with no customers. The mining fleet is an option on hardware that has not yet shown a published hashrate print.
Shareholders approved the conversion math and a name change to United Compute at the early-September special meeting. Nasdaq separately flagged the still-missing mid-year quarterly report and set an October deadline for a cure plan. The investment debate is whether a hosted Scrypt fleet and a coin treasury can be stood up before dilution, listing risk, and cash burn consume the public float. The next operating print either shows rigs hashing or another financing stacked on another reverse split.